BioOutsource Ltd. Acquired by Sartorius Stedim Biotech
Takeover expands SSB’s service portfolio
Glasgow, April 17, 2015 – BioOutsource Ltd. (BioOutsource), a leading provider of contract testing services for the biopharmaceutical industry, has been acquired by Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries. BioOutsource provides contract testing services to Global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. This acquisition will develop SSB’s service offering throughout the drug development pathway. The contractual parties agreed not to disclose any further details of the transaction.
Welcoming the acquisition, Gerry MacKay, CEO of BioOutsource said “We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services. As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing. We would also like to take this opportunity to thank one of our original shareholders Scottish Investment Bank, the investment arm of Scottish Enterprise, for their continued investment and support over the last 7 years”.
Reinhard Vogt, member of SSB’s Board, commented: “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.